Cingulate Inc., a clinical stage biopharmaceutical company, focuses on the development of product candidates for the treatment of central nervous system and neurobiological disorders. The company' lead product candidates are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for the treatment of attention deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
$1.21 +0.02 (1.68%)
As of 05/23/2022 16:00:00 EST IEX book CBOE book
2022 © Stock Market MBA, Inc.